Kenneth Samet Net Worth

The estimated Net Worth of Kenneth A Samet is at least $1.79 Milione dollars as of 15 August 2019. Mr. Samet owns over 7,200 units of Luminex Corp stock worth over $1,451,303 and over the last 9 years he sold LMNX stock worth over $103,000. In addition, he makes $238,426 as Independent Director at Luminex Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Samet LMNX stock SEC Form 4 insiders trading

Kenneth has made over 3 trades of the Luminex Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 7,200 units of LMNX stock worth $50,688 on 15 August 2019.

The largest trade he's ever made was buying 25,000 units of Luminex Corp stock on 18 November 2016 worth over $61,750. On average, Kenneth trades about 2,413 units every 67 days since 2015. As of 15 August 2019 he still owns at least 39,235 units of Luminex Corp stock.

You can see the complete history of Mr. Samet stock trades at the bottom of the page.

Kenneth Samet biography

Kenneth A. Samet serves as Independent Director of the Company. He has served as Chief Executive Officer of MedStar Health, Inc., a non-profit healthcare delivery system, since 2008. He previously served as that organization’s President from 2003 and as Chief Operating Officer from 1998. From 1990 to 2000, Mr. Samet served as President of MedStar Washington Hospital Center. From the mid-1980s to 1990, he held a variety of leadership positions with the Medlantic Healthcare Group. Mr. Samet served as a director of Catalyst Health Solutions, Inc., a public company, from April 2006 to July 2012, and has served as a Director of Cogentix Medical, Inc., a public company, since July 2016, and as a Director of Evolent Health, Inc., a public company, since September 2015. Mr. Samet received a bachelor’s degree in business administration from the Old Dominion University and a master’s degree in health services administration from the University of Michigan.

What is the salary of Kenneth Samet?

As the Independent Director of Luminex Corp, the total compensation of Kenneth Samet at Luminex Corp is $238,426. There are 5 executives at Luminex Corp getting paid more, with Nachum Shamir having the highest compensation of $3,362,140.

How old is Kenneth Samet?

Kenneth Samet is 62, he's been the Independent Director of Luminex Corp since 2018. There are 7 older and 7 younger executives at Luminex Corp. The oldest executive at Luminex Corp is Thomas Erickson, 69, who is the Independent Director.

What's Kenneth Samet's mailing address?

Kenneth's mailing address filed with the SEC is 12212 TECHNOLOGY BLVD, , AUSTIN, TX, 78727.

Insiders trading at Luminex Corp

Over the last 21 years, insiders at Luminex Corp have traded over $55,627,864 worth of Luminex Corp stock and bought 685,936 units worth $10,423,148 . The most active insiders traders include G Walter Ii Loewenbaum, Douglas C Bryant e Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of $888,944. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth $97,235.

What does Luminex Corp do?

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Complete history of Mr. Samet stock trades at Luminex Corp e Evolent Health Inc

Luminex Corp executives and stock owners

Luminex Corp executives and other stock owners filed with the SEC include:

• Nachum Shamir,
  President, Chief Executive Officer, Director
• Harriss Currie,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard Rew,
  Senior Vice President, General Counsel and Corporate Secretary
• Todd Bennett,
  Senior Vice President - Global Sales and Customer Operations
• Randall Myers,
  Senior Vice President - Global Manufacturing and Quality
• Kenneth Samet,
  Independent Director
• Kevin McNamara,
  Independent Director
• Jimmy Kever,
  Independent Director
• Edward Ogunro,
  Lead Independent Director
• Thomas Erickson,
  Independent Director
• Stephen Eck,
  Independent Director
• Dijuana Lewis,
  Independent Director
• Eric Shapiro,
  Senior Vice President - Global Marketing
• Nancy Fairchild,
  Senior Vice President - Human Resources
• Chuck Collins,
  Senior Vice President - Research and Development
• Robert J Cresci,
  Director
• Tadd S. Lazarus,
  SVP, Chief Medical Officer
• Jay B Johnston,
  Director
• Russell S Bradley,
  VP, Strategic Planning and Bus
• G Walter Ii Loewenbaum,
  Director
• Jim D Kever,
  Director
• Gregory J Gosch,
  Vice President - Marketing
• Charles J. Collins,
  SR VP, R&D - US
• John C Carrano,
  VP, Research & Development
• J Stark Phd Thompson,
  Director
• Douglas C Bryant,
  EVP, Chief Operating Officer
• James W Jacobson,
  VP, Research & Development
• Oliver H Meek,
  VP, Manufacturing
• Randel S Martin,
  VP, Marketing/Sales
• Kristi M Richburg,
  Controller
• G Walter Ii Loewenbaum,
  Director
• C Thomas Caskey,
  Director
• Laurence E Hirsch,
  Director
• Fred C Jr Goad,
  Director
• Jeremy K Bridge Cook,
  VP, Luminex Molecular Diagn
• Michael F Pintek,
  SVP Operations
• Patrick J Balthrop,
  President, Chief Exec. Officer
• Timothy R Dehne,
  VP, Systems R&D
• David S Reiter,
  General Counsel & Secretary
• Gerard Vaillant,
  Director